SpectraCure AB (publ) OMXSTO:SPEC:
APPOINTS JOHANNES SWARTLING AS CEO EFFECTIVE OCT 1, 2025
MASOUD KHAYYAMI STEPS DOWN AS INTERIM CEO
Spectracure Appoints Johannes Swartling As CEO
Earlier from SpectraCure
- Spectracure Reports Positive Results In Prostate Cancer Study
- SPEC: Clinical progress and new funding strengthen position despite ongoing losses
- SPEC: Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies
- SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
- SPEC: Losses widened in Q3 as SpectraCure advances clinical studies and seeks new funding
Later from SpectraCure
- Spectracure Gets Approval To Commence Clinical Trial
- Spectracure Q-Pro Patent Approved In Japan
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
- Spectracure Q3 Net Loss SEK 35 Mln
Follow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure